CYP4A26P

Across TCGA pan-cancer cohorts, CYP4A26P RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated CYP4A26P data layer.

The strongest signal is observed in thymoma (THYM), where higher CYP4A26P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CYP4A26P expression acts as an unfavorable survival marker, although some lineages such as LUAD and ESCA show a favorable association.

THYM, LUAD, and STAD are the cancer types where CYP4A26P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Tertile	All	0.186	0.931	<.001	45	view →
LUAD	OS	Tertile	All	0.489	0.302	<.001	36	view →
STAD	OS	Tertile	II,III,IV	0.195	0.583	.007	27	view →
SKCM	DFS	Tertile	III,IV	0.029	0.597	<.001	21	view →
COAD	OS	Tertile	All	0.238	0.619	.025	12	view →
ESCA	DFS	Tertile	All	0.687	0.301	.031	9	view →
THCA	DFS	Tertile	IV	0.243	0.801	.021	9	view →
KIRC	DFS	Tertile	All	0.793	0.584	.035	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

CYP4A26P–THYM (OS)

Open the THYM breakdown →